Stifel Financial’s Arcturus Therapeutics ARCT Stock Holding History

Stifel Financial’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,714	Closed	-$13K	–	2583
2017 Q2	$13K	Sell	1,714 -2,215	-56%	-$17.8K	﹤0.01%	2548
2017 Q1	$31K	Hold	3,929	–	–	﹤0.01%	2483
2016 Q4	$58K	Sell	3,929 -2,200	-36%	-$32.9K	﹤0.01%	2395
2016 Q3	$105K	Sell	6,129 -2,728	-31%	-$88.1K	﹤0.01%	2286
2016 Q2	$278K	Buy	8,857 +2,257	+34%	+$71.1K	﹤0.01%	2077
2016 Q1	$175K	Sell	6,600 -429	-6%	-$14.5K	﹤0.01%	2032
2015 Q4	$309K	Buy	7,029 +3,186	+83%	+$143K	﹤0.01%	1896
2015 Q3	$162K	Buy	3,843 +86	+2%	+$4.52K	﹤0.01%	2075
2015 Q2	$172K	Sell	3,757 -1,857	-33%	-$85.1K	﹤0.01%	2203
2015 Q1	$221K	Buy	+5,614	New	+$247K	﹤0.01%	2060

Other funds holding ARCT

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

LCM

Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return

Stifel Financial's ARCT Position: Q3 2017 in Review

Stifel Financial sold out of Arcturus Therapeutics (ARCT) in Q3 2017, closing a stake of 1,714 shares — an estimated $13K sold.

Stifel Financial first reported a position in ARCT in Q1 2015 and held it in 10 quarters. The position peaked at $309K in Q4 2015. 24 funds tracked by Wall St. Rank hold ARCT as of Q3 2017.

Stifel Financial reported no remaining Arcturus Therapeutics position as of Q3 2017 after selling out during the quarter.
Stifel Financial sold 1,714 Arcturus Therapeutics shares in Q3 2017, an estimated $13K.
Stifel Financial first reported a position in Arcturus Therapeutics in Q1 2015 and held it in 10 quarters.
Stifel Financial's Arcturus Therapeutics position peaked at $309K in Q4 2015.
24 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2017.

Based on Stifel Financial's 13F filing for Q3 2017, filed 13 Nov 2017.